(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

The woolly mammoth has been extinct for thousands of years, but Colossal Biosciences is pursuing technology that could help ...

Colossal Biosciences raises $200M in Series C funding led by TWG Global, advancing its innovative de-extinction projects and ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report) and keeping the price target at ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Colossal Biosciences, which aims to revive extinct species, announced it has raised an additional $200 million. Critics say ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...